Atara Biotherapeutics, Inc. (ATRA), a clinical-stage biotechnology company, announced the departure of Carol Gallagher from its Board of Directors and appointed Brian Cherry to succeed her.
Brian brings more than 25 years of expertise from across the healthcare, industrial, business services, financial services, and consumer product industries.
He has contributed as a board member to the U.S. Air Force Academy Foundation and the Undergraduate Financial Aid Leadership Council.
Atara shares closed Friday at $10.41, down 0.48%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.